Advances in Alzheimer's disease's pharmacological treatment.

Autor:	Conti Filho CE; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Loss LB; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Marcolongo-Pereira C; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Rossoni Junior JV; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Barcelos RM; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Chiarelli-Neto O; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., da Silva BS; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Passamani Ambrosio R; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Castro FCAQ; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Teixeira SF; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil., Mezzomo NJ; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2023 Jan 26; Vol. 14, pp. 1101452. Date of Electronic Publication: 2023 Jan 26 (Print Publication: 2023).
DOI:	10.3389/fphar.2023.1101452
Abstrakt:	Alzheimer's disease (AD) is the most common type of dementia in the elderly. Several hypotheses emerged from AD pathophysiological mechanisms. However, no neuronal protective or regenerative drug is available nowadays. Researchers still work in drug development and are finding new molecular targets to treat AD. Therefore, this study aimed to summarize main advances in AD pharmacological therapy. Clinical trials registered in the National Library of Medicine database were selected and analyzed accordingly to molecular targets, therapeutic effects, and safety profile. The most common outcome was the lack of efficacy. Only seven trials concluded that tested drugs were safe and induced any kind of therapeutic improvement. Three works showed therapeutic effects followed by toxicity. In addition to aducanumab recent FDA approval, antibodies against amyloid-β (Aβ) showed no noteworthy results. 5-HT6 antagonists, tau inhibitors and nicotinic agonists' data were discouraging. However, anti-Aβ vaccine, BACE inhibitor and anti-neuroinflammation drugs showed promising results. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Conti Filho, Loss, Marcolongo-Pereira, Rossoni Junior, Barcelos, Chiarelli-Neto, Silva, Passamani Ambrosio, Castro, Teixeira and Mezzomo.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu